Neuroblastoma is the most common solid extracranial tumor in children, and congenital forms account for 5% of all neuroblastoma cases. Diagnosis in utero is very rare, and their evolution leading to premature delivery for urgent treatment is exceptional. In some of these cases, chemotherapy is required after birth, in the face of tumor progression that threatens functional (dumbbell neuroblastoma), or even vital prognosis (stage 4S). However, the optimal doses of chemotherapy in premature newborns are not known. In this article, we review the management of six patients treated in French pediatric oncology centers, in order to analyze the treatment modalities, and report on their tolerance as well as the outcome of these newborns.